Becton Dickinson and Company Limited

University of Michigan

John D DeNuzzio

Steven Keith

William J Allen

Todd M Chelak

J Bruce Pitner

Lee Griswold

Robert E West

Douglas Byron Sherman

Lawrence A Monahan

Kristin Weidemaier

Ross Jacobson

Phyllis J Palmer

Christopher C Herdman

Bill Stewart

Frederick Karl

Terry J Amiss

Javier Alarcon

Michael I Bernhard

William E Strohben, Jr

Ronald J Pettis

Mark A Burns

Wayne F Beyer

Glenn P Vonk

Noel G Harvey

Randal A Hoke

Brian N Johnson

Hans C Evers

David T Burke

Terry J Amis

Bernt Fredrick Broberg

Robert S Parker

Javier Alarcón

Ross Wayne Jacobson

A lancing device integrated with a sensing strip and method of making and using the same are provided. A lance and analyte sensing strip are combined in a single, preferably disposable, device. In a preferred embodiment, a slot is provided in a support member so the lance can be engaged by a lance driver and driven into the skin producing a bodily fluid sample from a wound. The sensing area of the sensing strip is adjacent to the wound location reducing dexterity requirements for patients.

Integrated lancet and bodily fluid sensor

A device for sensing analyte concentration, and in particular glucose concentration, in vivo or in vitro is disclosed. An optical conduit, preferably an optical fiber has an optical system at the proximal end of the optical conduit. A sensing element is attached to the distal end of the optical conduit, and comprises at least one binding protein adapted to bind with at least one target analyte. The sensing element further comprises at least one reporter group that undergoes a luminescence change with changing analyte concentrations. Optionally, the sensing element includes reference groups with luminescence properties that are substantially unchanged by variations in the analyte concentrations.

Fiber optic device for sensing analytes

A device for sensing analyte concentration, and in particular glucose concentration, in vivo or in vitro is disclosed. A sensing element is attached to the distal end of an optical conduit, and comprises at least one binding protein adapted to bind with at least one target analyte. The sensing element further comprises at least one reporter group that undergoes a luminescence change with changing analyte concentrations. Optionally, the optical conduit and sensing element may be housed within a cannulated bevel.

Fiber optic device for sensing analytes and method of making same

A device for sensing analyte concentration, and in particular glucose concentration, in vivo or in vitro is described. An optical conduit, preferably an optical fiber, has an optical system at the proximal end of the optical conduit. A sensing element is attached to the distal end of the optical conduit, and may include at least one binding protein adapted to bind with at least one target analyte. The sensing element further may also include at least one reporter group that undergoes a luminescence change with changing analyte concentrations. Optionally, the sensing element includes reference groups with luminescence properties that are substantially unchanged by variations in the analyte concentrations.

A minimally-invasive analyte detecting device and method for using the same. The system and method employ a device having an active electrode optionally coated with a substance, and a counter-electrode that is configured at least partially surround the active electrode. The configuration of the auxiliary electrode and active electrode improves the current flow through the device and increases the sensitivity of the device. When the device is placed against the patient's skin, the active electrode is adapted to enter through the stratum corneum of a patient to a depth less than a depth in the dermis at which nerve endings reside. An electric potential is applied to the active electrode and the analyte level is determined based on the amount of current or charge flowing through the device.

Minimally-invasive system and method for monitoring analyte levels

A closed loop therapy system for controlling a concentration of a substance, such as blood glucose concentration, in the body of a user. The system and method employ a sensor system that measures a glucose level in the body, a controller that uses the measured glucose levels to generate an output that can be used to automatically or manually control an intradermal insulin infusion system to set a constant or time-varying profile of target blood glucose concentrations in a user, and then infuse an appropriate amount of insulin into the body of the user so as to reach and maintain the target values of the blood glucose concentration.

System and method for initiating and maintaining continuous, long-term control of a concentration of a substance in a patient using a feedback or model-based controller coupled to a single-needle or multi-needle intradermal (ID) delivery device

Disclosed are methods and compositions for isothermal amplification of nucleic acids in a microfabricated substrate. Methods and compositions for the analysis of isothermally amplified nucleic acids in a microfabricated substrate are disclosed as well. The microfabricated substrates and isothermal amplification and detection methods provided are envisioned for use in various diagnostic methods, particularly those connected with diseases characterized by altered gene sequences or gene expression.

Chip-based isothermal amplification devices and methods

A user activated iontophoretic device of the present invention includes an electrode assembly, an electrode reservoir and at least one drug reservoir. The device is divided or otherwise separated into at least two portions, with one portion containing the electrode reservoir and the other containing the drug reservoir, which may include a medication in a dry form. In one embodiment, the two portions are each contained in separate compartments of a pouch. In another embodiment, the portions are contained in a single compartment and divided by a barrier. A method of activating the device includes causing the two portions to come into electrical conducting contact with one another to at least partially hydrate one of the reservoirs. This can be accomplished, for example, by either folding the device to bring the two portions into contact with one another or simply by removing the barrier dividing the two portions. In the alternative, the device may include two separate portions which can be brought together to activate the device. In this way, the device is suitable for use to deliver a high dose efficiency, while providing a commercially suitable shelf-life.

User activated iontophoertic device

A user activated iontophoretic device of the present invention includes an electrode assembly, an electrode reservoir and at least one drug reservoir. The device is divided or otherwise separated into at least two portions, with one portion containing the electrode reservoir and the other containing the drug reservoir, which may include a medication in a dry form. The electrode reservoir and the drug reservoir are sealingly separated by a barrier, which can be removed to bring the reservoirs into fluid conducting contact with one another. A method of activating the device includes causing the two portions to come into fluid conducting contact with one another to at least partially hydrate one of the reservoirs. This can be accomplished by removing the barrier dividing the two portions. In this way, the device is suitable for use to deliver a drug which has limited stability in an aqueous solution.

User activated iontophoretic device and method for activating same

An iontophoretic drug delivery system including a patch, a controller and a magazine. The patch may be secured in a compartment formed in the magazine so that upon insertion of the controller along the magazine to fasten the controller to the patch, a dry drug contained in the patch is hydrated and the patch and controller can be removed from the magazine for attachment to the skin of a patient.

Iontophoretic drug delivery system, including method for activating same

Growing community of inventors

Chapel Hill, NC, United States of America

John D DeNuzzio